Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 4/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.49 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6136973 | 0.84 | CYP2A6 (0.50) | CYP11B1CYP11B2S1PR4CYP3A4CYP2D6 | |
| SCHEMBL2842190 | 0.76 | S1PR4 (0.54) | S1PR4CYP3A4CYP2D6CYP2C9NPC1 | |
| SCHEMBL4158695 | 0.76 | S1PR4 (0.54) | S1PR4CYP3A4CYP2D6CYP2C9NPC1 | |
| SCHEMBL6136856 | 0.76 | CYP11B1 (0.51) | CYP11B1CYP11B2ABCB1CYP3A4CYP2D6 | |
| SCHEMBL6136943 | 0.76 | PDE4A (0.53) | CYP11B1CYP11B2RAB9ALMNAPDE4A | |
| SCHEMBL91148 | 0.74 | S1PR4 (0.55) | CYP11B1CYP11B2S1PR4CYP3A4CYP2C9 | |
| SCHEMBL9980697 | 0.74 | S1PR4 (0.55) | S1PR4CYP3A4CYP2D6CYP2C9NPC1 | |
| SCHEMBL4155091 | 0.74 | S1PR4 (0.55) | S1PR4CYP3A4CYP2C9NPC1RAB9A | |
| SCHEMBL6136743 | 0.74 | CYP11B1 (0.41) | CYP11B1CYP11B2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6136676 | 0.73 | S1PR4 (0.40) | CYP11B1CYP11B2S1PR4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1120409-B1 | 2,3-DISUBSTITUTED PYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, DRUG COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES FOR THE PREPARATION | DAINIPPON PHARMACEUTICAL CO (JP) | 2005-01-26 | — | — | EP | disclosed |
| US-6765095-B2 | HETEROCYCLIC IMINES SUCH AS 2-PHENOXY-3-(3-(PYRIDIN-4-YL)-PROPOXY)PYRIDINE, FORMED BY ETHERIFICATION, AMINATION OR SULIFIDING, FOR USE AS PHOSPHODIESTERASE INHIBITORS | DAINIPPON PHARMACEUTICAL COMPANY, LIMITED (JP) | 2004-07-20 | — | — | US | disclosed |
| US-6683186-B2 | CONDENSATION, ETHERIFICATION; PHOSPHODIESTERASE INHIBITORS; ANTIALLERGENS, ANTIINFLAMMATORY AND ANTIASTHMATIC AGENTS | DAINIPPON PHARMACEUTICAL COMPANY, LIMITED (JP) | 2004-01-27 | — | — | US | disclosed |
| US-20030199554-A1 | 2,3-Disubstituted pyridine derivative, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor | KAWASAKI MOTOJI (JP) | 2003-10-23 | — | — | US | disclosed |
| US-20030195232-A1 | 2,3-Disubstituted pyridine derivative, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor | KAWASAKI MOTOJI (JP) | 2003-10-16 | — | — | US | disclosed |
| US-6555557-B1 | 2-(3-chlorophenoxy)-3-(3-(3-hydroxypyridin-5-yl)propoxy) -pyridine, for example; phosphodiesterase IV inhibitors | DAINIPPON PHARMACEUTICAL COMPANY, LIMITED (JP) | 2003-04-29 | — | — | US | disclosed |
| EP-1120409-A1 | 2,3-DISUBSTITUTED PYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, DRUG COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES FOR THE PREPARATION | Dainippon Pharmaceutical Co., Ltd. (JP) | 2001-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199554-A1 | 2,3-Disubstituted pyridine derivative, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor | NOX1, CYP4A11, PDE12 | CYP11B1 18/4885CYP11B2 25/4885S1PR4 896/4885 |
| US-20030195232-A1 | 2,3-Disubstituted pyridine derivative, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor | NOX1, CYP4A11, PDE12 | CYP11B1 18/4885CYP11B2 25/4885S1PR4 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.